AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2360387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine as laryngotracheal spray (1 mg/kg BW)
Number of subjects: 80
Study 2360387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine as transtracheal injection (1 mg/kg BW)
Number of subjects: 80
Study 2360387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine as intravenous injection (1 mg/kg BW)
Number of subjects: 80
Study 2360387 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 80
Study 118805 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethylmelamine (HMM) alone, 300 mg/m2/day x 14 days every 21 days
Number of subjects: 53
Study 118805 — intervention group
Group type: EXPERIMENTAL
Intervention: HOM regimen (HMM 200 mg/m2/day x 21 days, vincristine 1.5 mg on Days 1, 8, and 15, mitomycin C 12 mg/m2 once every 6 weeks)
Number of subjects: 53
Study 118805 — intervention group
Group type: COMPARATOR
Intervention: Hexamethylmelamine (HMM) alone
Number of subjects: 53
Study 118805 — intervention group
Group type: COMPARATOR
Intervention: HOM regimen
Number of subjects: 53
Study 31653669 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.01%) eye-drops, one drop in each eye every day for 2 years
Number of subjects: 289
Study 31653669 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye-drops, one drop in each eye every day for 2 years
Number of subjects: 289
Study 31484647 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib + Lenalidomide + Dexamethasone (VRD) for 6 cycles followed by autologous stem cell transplant (ASCT)
Number of subjects: 458
Study 31484647 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib + Lenalidomide + Dexamethasone (VRD)
Number of subjects: 458
Study 28186634 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource Diary (RD) intervention over 4 weeks
Number of subjects: 89
Study 28186634 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study 25841542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg daily
Number of subjects: 138
Study 25841542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 23478192 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training plus education
Number of subjects: 24
Study 23478192 — intervention group
Group type: COMPARATOR
Intervention: Education only
Number of subjects: 24
Study 21120738 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention about the regulation of dietary supplements under the DSHEA
Number of subjects: 0
Study 21120738 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no educational intervention)
Number of subjects: 0
Study 21120738 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA approval information manipulation
Number of subjects: 0
Study 19486798 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-flap LASIK/sub-Bowman keratomileusis (SBK)
Number of subjects: 50
Study 19486798 — intervention group
Group type: COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 50
Study 18050183 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment in group A (G/A genotype)
Number of subjects: 86
Study 18050183 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment in group G (G/G genotype)
Number of subjects: 86
Study 15758606 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-waveform analysis of the fetal electrocardiogram (ECG)
Number of subjects: 8000
Study 15758606 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated ST analysis added to fetal heart rate trace
Number of subjects: 8000
Study 11888512 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG CoA RI therapy (pravastatin 40 mg QD or simvastatin 20 mg QD)
Number of subjects: 37
Study 11888512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9475818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate 100 mg
Number of subjects: 49
Study 9475818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 8545877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir treatment
Number of subjects: 149
Study 8545877 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 149
Study 759413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid usage in Group A (mean age 27.6 years, N=50)
Number of subjects: 50
Study 759413 — intervention group
Group type: COMPARATOR
Intervention: Hearing aid usage in Group B (mean age 75.06 years, N=50)
Number of subjects: 50
Study 31133474 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (n = 65)
Number of subjects: 130
Study 31133474 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n = 65)
Number of subjects: 130
Study 29392372 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (target BrAC of 0.080%)
Number of subjects: 64
Study 29392372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27430340 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AG)
Number of subjects: 250
Study 27430340 — intervention group
Group type: COMPARATOR
Intervention: No Acupuncture (NAG)
Number of subjects: 250
Study 25344738 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy
Number of subjects: 0
Study 25344738 — intervention group
Group type: COMPARATOR
Intervention: Type I IFN or CXCL10
Number of subjects: 0
Study 22955258 — intervention group
Group type: EXPERIMENTAL
Intervention: pAMPK-positive group
Number of subjects: 74
Study 22955258 — intervention group
Group type: EXPERIMENTAL
Intervention: pAMPK-negative group
Number of subjects: 74
Study 20100992 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha‐adrenoceptor antagonist)
Number of subjects: 13
Study 20100992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (calcium channel blocker)
Number of subjects: 13
Study 20100992 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine increase during phentolamine infusion
Number of subjects: 13
Study 18068060 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (30 mg/kg bolus, 10 mg/kg/h infusion for 48 hours)
Number of subjects: 24
Study 16025972 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus TGP
Number of subjects: 61
Study 16025972 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 61
Study 11994882 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lavender oil aromatherapy stream administered for a two hour period every other day for a total of ten treatment sessions.
Number of subjects: 15
Study 11994882 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water) administered for a two hour period every other day for a total of ten treatment sessions.
Number of subjects: 15
Study 10327088 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm suspended by a balancer
Number of subjects: 12
Study 10327088 — intervention group
Group type: COMPARATOR
Intervention: Forearm not suspended (control)
Number of subjects: 12
Study 10327088 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher work area position
Number of subjects: 12
Study 8590749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (exercise training, psychosocial support, education)
Number of subjects: 0
Study 8590749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation for surgical patients
Number of subjects: 0
Study 8590749 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of risk factors in patients with known coronary disease
Number of subjects: 0
Study 8590749 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent studies on cardiac rehabilitation
Number of subjects: 0
Study 8590749 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and return to work after bypass surgery
Number of subjects: 0
Study 8590749 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncardiac complications of surgery
Number of subjects: 0
Study 2187896 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical wadding of the axillary fossa with the use of proximate muscular tissue
Number of subjects: 53
Study 380732 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) weekly subcutaneous injections in addition to standard treatment
Number of subjects: 26
Study 380732 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 26
Study 30859184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg q8h
Number of subjects: 12
Study 30859184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 50 mg q6h
Number of subjects: 12
Study 30859184 — intervention group
Group type: COMPARATOR
Intervention: Both dosing regimens
Number of subjects: 12
Study 25683204 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score-based screening starting at age 47 for top 5% risk group, screening every four years starting at age 55 for median group
Number of subjects: 0
Study 25683204 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened interscreening interval for high risk group
Number of subjects: 0
Study 25683204 — intervention group
Group type: COMPARATOR
Intervention: Standard screening every four years starting at age 55 for median risk group
Number of subjects: 0
Study 23915086 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning of the base rate
Number of subjects: 0
Study 23915086 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning of the repetition rate
Number of subjects: 0
Study 23915086 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of base rate and repetition rate learning
Number of subjects: 0
Study 23915086 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related potentials and stimulus discriminability manipulations
Number of subjects: 0
Study 21324590 — intervention group
Group type: EXPERIMENTAL
Intervention: CST plus sertraline
Number of subjects: 0
Study 21324590 — intervention group
Group type: EXPERIMENTAL
Intervention: CST plus placebo
Number of subjects: 0
Study 21324590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline alone
Number of subjects: 0
Study 21324590 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 0
Study 19270316 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum YKL-40 concentration
Number of subjects: 4298
Study 17299655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative improvements including thorough preoperative haematological checks, administration of inhibitors of fibrinolysis (aprotinin, ε‐aminocaproic acid), minimization of extracorporeal circulation (ECC), and postoperative recovery measures (i.v. iron and recombinant human erythropoietin).
Number of subjects: 0
Study 17299655 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern blood product quality and real-time monitoring of haemorrhagic/thrombogenic risk using thrombelastography analysis.
Number of subjects: 0
Study 17299655 — intervention group
Group type: EXPERIMENTAL
Intervention: Setting transfusion trigger based on haemoglobin concentration to as low as 70 g/l in suitable patients.
Number of subjects: 0
Study 15188791 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal pharmacologic magnesium sulfate (MgSO4)
Number of subjects: 0
Study 15188791 — intervention group
Group type: COMPARATOR
Intervention: High-dosage magnesium sulfate (MgSO4) for tocolysis
Number of subjects: 0
Study 15188791 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage magnesium sulfate (MgSO4)
Number of subjects: 0
Study 11721504 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast 10mg/day
Number of subjects: 32
Study 11721504 — intervention group
Group type: EXPERIMENTAL
Intervention: montelukast (addition to standard therapy)
Number of subjects: 32
Study 11721504 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy: intra-nasal corticosteroids)
Number of subjects: 32
Study 9220522 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin inhalation before hypertonic saline (HS) challenge
Number of subjects: 21
Study 9220522 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (HS) challenge alone
Number of subjects: 21
Study 8116057 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily proguanil (PROG)
Number of subjects: 170
Study 8116057 — intervention group
Group type: COMPARATOR
Intervention: Once weekly chloroquine (CQ)
Number of subjects: 170
Study 8116057 — intervention group
Group type: EXPERIMENTAL
Intervention: Two drug combination (CQ+PROG)
Number of subjects: 170
Study 3321924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 14
Study 3321924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31122144 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard practice of titrating heparin to activated partial thromboplastin times goal of 45-55 seconds (Arm 1)
Number of subjects: 10
Study 31122144 — intervention group
Group type: COMPARATOR
Intervention: Non-titrating weight-based heparin infusion (10 units/kg/h) (Arm 2)
Number of subjects: 10
Study 31601214 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 911
Study 26287803 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning course
Number of subjects: 39
Study 26287803 — intervention group
Group type: COMPARATOR
Intervention: lecture-based course
Number of subjects: 39
Study 25376670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-length laser therapy (iLux-Triax) and tecar therapy (Pharon), treated three times a week for a total of 10 sessions.
Number of subjects: 66
Study 25376670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-length laser therapy (iLux-Triax) and tecar therapy (Pharon) in patients with low-back pain and leg pain.
Number of subjects: 66
Study 24187727 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty-designed intervention
Number of subjects: 346
Study 24187727 — intervention group
Group type: COMPARATOR
Intervention: Usual honor code exposure
Number of subjects: 346
Study 21471553 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm subjects
Number of subjects: 49
Study 21471553 — intervention group
Group type: COMPARATOR
Intervention: Term subjects
Number of subjects: 49
Study 18637086 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow permissive time ≤ 2.5 s
Number of subjects: 50
Study 18637086 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mmHg peristaltic amplitude
Number of subjects: 50
Study 16926581 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary treatment consisting of education, exercise and stretch, goal setting, medication management, and cognitive and behavioral techniques.
Number of subjects: 99
Study 16926581 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary treatment
Number of subjects: 99
Study 15592276 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin injection (3.6 mg/month)
Number of subjects: 147
Study 15592276 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 147
Study 11697019 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence to HAART (measured by PMAQ-V1.0)
Number of subjects: 194
Study 9018388 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine and Fluoxetine (SSRIs)
Number of subjects: 21
Study 9018388 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study 8276043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg taken once daily with breakfast
Number of subjects: 24
Study 8276043 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg taken once daily with evening meal
Number of subjects: 24
Study 8276043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2437417 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 77
Study 2437417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (Acyclovir and Inosine Pranobex)
Number of subjects: 77
Study 2437417 — intervention group
Group type: COMPARATOR
Intervention: Inosine Pranobex
Number of subjects: 77
Study 31973631 — intervention group
Group type: COMPARATOR
Intervention: Local vibration
Number of subjects: 24
Study 31973631 — intervention group
Group type: COMPARATOR
Intervention: Graduated compression stockings
Number of subjects: 24
Study 31973631 — intervention group
Group type: COMPARATOR
Intervention: Graduated compression stockings + local vibration
Number of subjects: 24
Study 29870501 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisession behavioral intervention plus antiretrovirals
Number of subjects: 0
Study 29870501 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisession behavioral intervention
Number of subjects: 0
Study 29870501 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV counseling
Number of subjects: 0
Study 27615712 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-TAVI
Number of subjects: 58
Study 27615712 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 58
Study 27615712 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-TAVI and SAVR
Number of subjects: 58
Study 25078372 — intervention group
Group type: EXPERIMENTAL
Intervention: scFOS-supplemented formula (4 g/L scFOS)
Number of subjects: 61
Study 25078372 — intervention group
Group type: COMPARATOR
Intervention: placebo-supplemented formula (4 g/L maltodextrins)
Number of subjects: 61
Study 21270839 — intervention group
Group type: EXPERIMENTAL
Intervention: cis‐9, trans‐11 CLA
Number of subjects: 61
Study 21270839 — intervention group
Group type: EXPERIMENTAL
Intervention: industrial trans fatty acids
Number of subjects: 61
Study 21270839 — intervention group
Group type: COMPARATOR
Intervention: oleic acid
Number of subjects: 61
Study 20723569 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 15
Study 20723569 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric voluntary muscular contraction (VOL)
Number of subjects: 15
Study 20723569 — intervention group
Group type: COMPARATOR
Intervention: PRE condition
Number of subjects: 15
Study 20723569 — intervention group
Group type: COMPARATOR
Intervention: POST condition
Number of subjects: 15
Study 20723569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NMES and VOL
Number of subjects: 15
Study 18222648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST)
Number of subjects: 0
Study 18222648 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 16319311 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral temporal lobectomy patients
Number of subjects: 62
Study 16319311 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 62
Study 16319311 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with declarative memory of contingencies
Number of subjects: 62
Study 12736485 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP (25 microg intracoronary injection + 0.025 microg x kg(‐1) x min(‐1) intravenous infusion for 1 week)
Number of subjects: 19
Study 12736485 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 19
Study 11705173 — intervention group
Group type: COMPARATOR
Intervention: Compression stockings (Group 1)
Number of subjects: 274
Study 11705173 — intervention group
Group type: COMPARATOR
Intervention: 0.3 ml low‐molecular weight heparin (Group 2)
Number of subjects: 274
Study 11705173 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings and 0.3 ml LMWH (Group 3)
Number of subjects: 274
Study 9140691 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 20 mg iv (two doses of 10 mg each)
Number of subjects: 16
Study 9140691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml, two doses)
Number of subjects: 16
Study 8198250 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms per nasal cavity and day)
Number of subjects: 22
Study 8198250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3491317 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 64
Study 3491317 — intervention group
Group type: COMPARATOR
Intervention: Portacaval shunt
Number of subjects: 64
Study 3491317 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy and Portacaval shunt
Number of subjects: 64
Study 29468749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy lifestyle counselling
Number of subjects: 75
Study 29468749 — intervention group
Group type: COMPARATOR
Intervention: Regular-fat cheese
Number of subjects: 75
Study 27228899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored online intervention for physicians including audio-recorded clips
Number of subjects: 527
Study 27228899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored online intervention for physicians
Number of subjects: 527
Study 25104521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 216
Study 25104521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 24506965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose carvedilol combined with candesartan
Number of subjects: 40
Study 24506965 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy alone)
Number of subjects: 40
Study 20843983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 231
Study 17588584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 92
Study 17588584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 16652033 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of abacavir/lamivudine (FDC)
Number of subjects: 186
Study 16652033 — intervention group
Group type: COMPARATOR
Intervention: Separate entities (abacavir twice daily and lamivudine once daily) (SE)
Number of subjects: 186
Study 12814254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy (vincristine, lomustine, and prednisone or '8-in-1') with involved-field irradiation
Number of subjects: 250
Study 12814254 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field irradiation with chemotherapy
Number of subjects: 250
Study 12814254 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 250
Study 11009150 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose anthelminthic (400 mg albendazole)
Number of subjects: 0